← Back to Search

Metabolic MRI for Brain Cancer

Phase 1
Recruiting
Led By Dirk Mayer, Dr. rer. nat
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Suitable to undergo contrast-enhanced MRI
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within three years post treatment
Awards & highlights

Study Summary

This trial will study the safety and feasibility of using hyperpolarized metabolic MRI to diagnose brain tumors.

Who is the study for?
This trial is for adults aged 18-80 with a new or previously diagnosed infiltrating glioma, such as various grades of astrocytoma and oligodendroglioma. Participants must be able to have an MRI with contrast and not be pregnant. Those who can't undergo MRI scans or receive IV contrast due to severe reactions or poor kidney function cannot join.Check my eligibility
What is being tested?
The study tests the safety and usefulness of hyperpolarized metabolic MRI using a substance called HP 13C-pyruvate in diagnosing brain tumors. It aims to see if this method is better than standard MRI imaging for patients with infiltrating gliomas.See study design
What are the potential side effects?
Since this trial focuses on diagnostic imaging rather than medication, side effects may include typical risks associated with MRIs like discomfort from lying still and loud noises during the scan, plus any potential reaction to the IV contrast used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can safely have an MRI with contrast.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within three years post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within three years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Accuracy of metabolic MRI to diagnose Glioma
Secondary outcome measures
Utility of metabolic MRI over standard MRI imaging in the diagnosis of Glioma cancer

Trial Design

1Treatment groups
Experimental Treatment
Group I: metabolic MRIExperimental Treatment1 Intervention
Single-arm study in patients who have Glioma Perform metabolic magnetic resonance imaging on patient have a Glioma cancer to understand if metabolic MRI can be safely performed on this population

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
692 Previous Clinical Trials
376,859 Total Patients Enrolled
Dirk Mayer, Dr. rer. nat1.01 ReviewsPrincipal Investigator - University of Maryland, Baltimore
University of Maryland, Baltimore

Media Library

Hyperpolarized 13C-Pyruvate Clinical Trial Eligibility Overview. Trial Name: NCT04772456 — Phase 1
Brain Tumor Research Study Groups: metabolic MRI
Brain Tumor Clinical Trial 2023: Hyperpolarized 13C-Pyruvate Highlights & Side Effects. Trial Name: NCT04772456 — Phase 1
Hyperpolarized 13C-Pyruvate 2023 Treatment Timeline for Medical Study. Trial Name: NCT04772456 — Phase 1
~0 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top